Adilia Hormigo

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/fb000300-5b1b-11ed-acc7-cb5943312b84.jpg

First Name

Adilia

Last Name

Hormigo

NPI

1427029461

Faculty ID

17230

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Hormigo's clinical expertise is the treatment of malignancies of the central nervous system and neurologic complications of cancer.

Research Focus

Dr. Hormigo’s translational research focuses on new strategies in cancer immunology, including personalized treatment for patients with malignant brain tumors, understanding and overcoming the tumor microenvironment resistance to treatment and defining biomarkers of treatment response. She has been a primary investigator on innovative clinical trials. Her work has been published in numerous peer-reviewed journals.

Elsevier Profile

EMR ID

94869

Biography

<p>Adilia Hormigo, MD, PhD, is Leader, Neuro-Oncology Program, Co-Leader, Neuro-Oncology Multidisciplinary Disease Team and Professor, Hematology-Oncology, Neurosurgery, and Microbiology &amp; Immunology at Montefiore Einstein. She is also a member of the Cancer Therapeutics Program. Her clinical expertise is the treatment of malignancies of the central nervous system and neurologic complications of cancer.</p><p>Dr. Hormigo earned her Doctor of Medicine with honors from the University of Lisbon and her Doctor of Philosophy from New York University. She pursued a residency in neurology at New York Presbyterian-Weill Cornell University/Memorial Sloan-Kettering Cancer Center. She also completed research and clinical neuro-oncology fellowships at Memorial Sloan-Kettering Cancer Center. In addition, she held faculty positions at Memorial Sloan-Kettering Cancer jointly with Cornell University and at the Icahn School of Medicine at Mount Sinai, where she served as Director of Neuro-Oncology and founded the Neuro-Oncology Fellowship Program.</p><p>Dr. Hormigo&rsquo;s translational research focuses on new strategies in cancer immunology, including personalized treatment for patients with malignant brain tumors, understanding and overcoming the tumor microenvironment resistance to treatment and defining biomarkers of treatment response. She has been a primary investigator on innovative clinical trials. Her work has been published in numerous peer-reviewed journals.</p><p>Dr. Hormigo is board certified in neurology and certified in neuro-oncology. She is a fellow of the American Neurological Association and a member of many professional societies, including the Society for Neuro-Oncology, the American Society of Clinical Oncology, the American Association for Cancer Research and the Society for the Immunotherapy of Cancer. In addition, she has received numerous awards and honors, including Excellence in Teaching the Neurology Clerkship at Cornell University and the Memorial Sloan-Kettering Cancer Center Society and Memorial Sloan-Kettering Brain Tumor Center awards. She also received recognition as a CRI -V Foundation Clinic and Laboratory Integration Program (CLIP) Investigator.</p>

Is Open Scheduling

Off

Justin Y. K. Tang

https://assets.montefioreeinstein.org/profiles/images/physphoto/Tang_Justin_MD_420x504.jpg

First Name

Justin

Last Name

Tang

NPI

1619385747

Faculty ID

16500

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

56697

Is Open Scheduling

Off

Katharine A. McNeill

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/507c4f00-3934-11ed-9b41-f32856b0701a.jpg

First Name

Katharine

Last Name

McNeill

NPI

1598995730

Faculty ID

15494

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

1542

Is Open Scheduling

Off

Shalom Kalnicki

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/89820450-b883-11ee-8618-fda8dc77c52b.jpg

First Name

Shalom

Last Name

Kalnicki

NPI

1942381371

Faculty ID

9551

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Kalnicki, a radiation oncologist, focuses on new technologies in the radiation treatment of cancer. He was a pioneer in the use of intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), target motion management with 4-D radiation planning, and functional tumor imaging with PET-CT (positron emission tomography &ndash; CAT scan) fusion techniques. Another area of interest is the use of stereotactic guidance in radiation treatment, specifically for stereotactic radiosurgery (SRS). All enhance precision of tumor targeting with radiation therapy, increasing dose to the tumor, while sparing surrounding normal tissues.<br />&nbsp;<br />Dr. Kalnicki's research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies. His clinical interests focus on head and neck, prostate, and breast cancers.</p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Kalnicki focuses on researching and implementing new technologies in the radiation treatment of cancer, with the aim of enhancing the dose to the tumor target while preserving normal tissues from radiation injury, potentially increasing tumor control and improving quality of life. His research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Radiation Oncology

Research Focus

An active researcher, Dr. Kalnicki is currently investigating innovative methods of radiation planning and delivery, including Intensity Modulated Radiation Therapy (IMRT), PET-CT fusion for radiation planning, 4-D treatment planning, target motion manage

Elsevier Profile

EMR ID

4214

Biography

<p>Dr. Kalnicki focuses on researching and implementing new technologies in the radiation treatment of cancer, with the aim of enhancing the dose to the tumor target while preserving normal tissues from radiation injury, potentially increasing tumor control and improving quality of life. He pioneered the use of intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), target motion management with 4-D radiation planning, stereotactic body radiation therapy (SBRT) and functional tumor imaging with PET-CT (positron emission tomography &ndash; CAT scan) fusion techniques. His research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies.</p><p>Dr. Kalnicki earned his medical degree at the University of Sao Paulo Medical School in Sao Paulo, Brazil. He completed his residency and fellowship in radiotherapy at Montefiore and Albert Einstein College of Medicine. He came to Montefiore and Einstein from the University of Pittsburgh, School of Medicine, where he was Vice Chairman for Clinical Affairs and Director of Radiation Oncology at the University of Pittsburgh Cancer Institute. </p><p>Prior to joining the University of Pittsburgh Cancer Institute, Dr. Kalnicki served as Chairman of the Department of Radiation Oncology at Allegheny University of Health Sciences in Pittsburgh. He is a member of many prominent professional societies. He has authored numerous articles and abstracts during his career and is a recipient of several awards, including the Fellowship Award from the American College of Radiation Oncology.</p>

Is Open Scheduling

Off

Hilda Haynes-Lewis

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/e7712260-3933-11ed-9b41-f32856b0701a.jpg

First Name

Hilda

Last Name

Haynes-Lewis

NPI

1306927736

Faculty ID

15628

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Clinical Type

Nurse Practitioner

EMR ID

9852

Is Open Scheduling

Off

Madhur K. Garg

https://assets.montefioreeinstein.org/profiles/images/8782-madhur-garg.jpg

First Name

Madhur

Last Name

Garg

NPI

1215018643

Faculty ID

8782

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<dl id="header_01" class="detail">
<dd id="biography">
<p>Dr. Garg is the Clinical Director of Radiation Oncology, Director of Montefiore-Einstein's Proton Therapy Program and Co-Director of Stereotactic Radiation Therapy Program at Montefiore Medical Center.</p>
<p>He earned his medical degree at King George&rsquo;s Medical College and completed his residency in radiation oncology at Rush-Presbyterian-St. Luke&rsquo;s Hospital in Chicago and Montefiore in New York City. He also completed a specialized fellowship at Wayne State University in Detroit.</p>
<p>Dr. Garg is the recipient of the prestigious American Society of Clinical Oncology&rsquo;s Young Investigator's Award and the Department of Defense Physician Research Award. He is listed as one of the &ldquo;New York Top Doctors,&rdquo; &ldquo;America&rsquo;s Top Oncologists&rdquo; and &ldquo;Best Doctors in America.&rdquo;</p>
<p>Dr. Garg serves on several Montefiore and Einstein committees, as well as international societies such as the American Society of Clinical Oncology, the American College of Radiology and the American Society for Radiation Oncology. He is on the review boards for several journals, including&nbsp;<em>International Journal of Radiation Oncology &bull; Biology &bull; Physics</em>.</p>
<p>Dr. Garg is a principal investigator of several national and international research studies involving novel cancer treatment modalities and is actively involved in quality of life and healthcare issues for cancer patients.</p>
<p>His areas of interest are as below:</p>
</dd>
</dl>
<p>1. Advanced Technologies in Radiation Oncology (IMRT and IGRT)</p>
<p>2. Stereotactic Radiosurgery (SRS) for brain and spinal cord tumors</p>
<p>3.Proton Therapy and Particle Therapy</p>
<p>4. Stereotactic Body Radiation Therapy (SBRT) for lung and liver malignancies</p>
<p>5. Functional imaging and adaptive planning for Head/Neck malignancies</p>
<p>6. Translational research involving role of Anti-Angiogenensis and Immunotherapy in radiation therapy</p>
<p>7. Addressing Disparties in Cancer Care</p>
<p>8. Diet, Nutrition and Cancer</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Advanced technologies in radiation oncology with a focus on stereotactic targeting, functional imaging and adaptive planning.

Research Focus

Translational research involving anti-angiogenesis and radiosensitivity. Dr. Garg is a principal investigator of several national and international research studies involving novel cancer treatment modalities and is actively involved in quality of life for cancer patients.

Elsevier Profile

Selected Publications

<p><strong>1. Garg MK</strong>, Tekyi-Mensah S, Bolton S, Velasco J, Pontes E, Wood Jr DP, Porter AT, Forman JD: <em>The impact of Post-Prostatectomy PSA nadir on outcomes&nbsp;&nbsp; following salvage radiotherapy</em>.&nbsp; Urology 1998; 51(6): 998-1002.</p>
<p>&nbsp; &nbsp; &nbsp; &nbsp;<br />2. Guha C, Parashar B, Deb NJ, <strong>Garg MK</strong>, Gorla GR, Singh A, Roy-Chowdhury N, Vikram B, Roy-Chowdhury J: <em>Normal hepatocytes correct serum bilirubin after repopulation of Gunn rat liver subjected to irradiation/partial resection</em>. Hepatology, 2002; 36: 354-62.<br />&nbsp;<br />3. Sood B, <strong>Garg MK</strong>, Avadhani J, Gorla G, Malhotra H, Deore S, Vikram B: <em>Predictive value of Linear Quadratic Model in the treatment of Cervix Cancer using High Dose Rate Brachytherapy. </em>Int J Radiat Oncol Biol Phys 2002; 54(5): 1377-1387.</p>
<p><strong>4. Garg MK</strong>, Yaparpalvi R, Beitler JJ: <em>Loss of Cervical Spinal Curvature during radiation therapy for head and neck cancers. </em>Int J Radiat Oncol Biol Phys 2004; 58(1):185-188.<br />&nbsp;</p>
<p><strong>5.Garg MK, </strong>Beitler JJ:&nbsp; <em>Controversies in management of neck in head and neck cancer. </em>Curr Treat Options Oncol 2004; 5(1): 35-40.<br />&nbsp;</p>
<p><strong>6.Garg MK</strong>, Sharma A, Gorla G, Jaggernauth W, Beitler, JJ: <em>Role of High Dose Rate Brachytherapy in management of Recurrent Keloids after Surgery and External Beam Radiation therapy. </em>Radiother Oncol 2004; 73(2): 233-236.</p>
<p>7. Novetsky A, Einstein M, Goldberg G, Hailpern S, Landau E, Fields A, Mutyala M, Kalnicki S, <strong>Garg MK</strong><em>: </em><em>Efficacy And Toxicity Of Concomitant Cisplatin With External Beam Pelvic Radiotherapy And Two High Dose Rate Brachytherapy Insertions For The Treatment Of Locally-Advanced Cervical Cancer</em>. Radiother Oncol. 2004 Nov;73(2):233-6.</p>
<p>8. Beitler JJ, <strong>Garg MK,</strong> Ahn A, Owen R, Smith R: &ldquo;<em>High Dose Rate (HDR) Brachytherapy plus Neck Dissection for Nodal Disease&rdquo;</em> Head Neck. 2008 Mar 7; [Epub ahead of print]<br />&nbsp;</p>
<p>9. A Mukhopadhaya, J Mendecki, X Dong, L Liu, S Kalnicki, <strong>M Garg,</strong> A Alfieri, C Guha: &ldquo;<em>Localized Hyperthermia Combined with Intratumoral Dendritic Cells Induces Systemic Antitumor Immunity&rdquo;. </em>Cancer Res. 2007 Aug 15;67(16):7798-806.<br />&nbsp;</p>
<p>10. J Belbin, A Bergman, M Brandwein-Gensler, Q Chen, G Childs, <strong>M Garg,</strong> M Haigentz, R Hogue-Angeletti, R Moadel, A Negassa, R Owen, MB Prystowsky¹, B Schiff, NF Schlecht, K Shifteh, RV Smith, X Zheng: <em>&ldquo;Head and Neck Cancer: Reduce and Integrate for Optimal Outcome.&rdquo; </em>Genes Genet Syst. 2007 Oct;82(5):403-8.<br />&nbsp;</p>
<p>11. Peter H. Ahn, MD and <strong>Madhur K. Garg, MD</strong>: &ldquo;<em>PET-CT in head and neck cancers for target delineation</em>.&rdquo; Semin Nucl Med. 2008 Mar;38(2):141-8.<br /><strong>&nbsp;</strong>Yaparpalvi R, Mutyala S, Gorla GR, Butler J, Mah D, <strong>Garg MK</strong>, Kalnicki S. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18782683?ordinalpos=3&amp;itool=Entr… vs. volumetric bladder and rectal doses in combined intracavitary-interstitial high-dose-rate brachytherapy: correlation and comparison with published Vienna applicator data.</a> Brachytherapy. 2008 Oct-Dec;7(4):336-42. Epub 2008 Sep 7.<br />&nbsp;</p>
<p>12. Ahn PH, Ahn AI, Lee CJ, Shen J, Miller E, Lukaj A, Milan E, Yaparpalvi R, Kalnicki S, <strong>Garg MK.</strong> &ldquo;<em><a href="http://www.ncbi.nlm.nih.gov/pubmed/19147027?ordinalpos=1&amp;itool=Entr… positional variation among the skull, mandible, and cervical spine with treatment progression during head-and-neck radiotherapy&rdquo;.</a></em> Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):626-33.<br />&nbsp;</p>
<p>13. Hong LX, Chen CC, <strong>Garg M,</strong> Yaparpalvi R, Mah D. &ldquo;<em><a href="http://www.ncbi.nlm.nih.gov/pubmed/19147020?ordinalpos=2&amp;itool=Entr… experiences with onboard imager KV images for linear accelerator-based stereotactic radiosurgery and radiotherapy setup.</a>&rdquo;</em> Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):556-61.<br />&nbsp;</p>
<p>14. Skinner WK, Muse ED, Yaparpalvi R, Guha C, <strong>Garg MK,</strong> Kalnicki S. <em>&ldquo;<a href="http://www.ncbi.nlm.nih.gov/pubmed/19854386">Obtaining normal tissue constraints using intensity modulated radiotherapy (IMRT) in patients with oral cavity, oropharyngeal, and laryngeal carcinoma.</a></em>&rdquo; Med Dosim. 2009 winter; 34(4):279-84. Epub 2008 Dec 26<br />&nbsp;</p>
<p>15. Lee CC, Wu A, <strong>Garg M,</strong> Mutyala S, Kalnicki S, Sayed G, Mah D <em>&ldquo;<a href="http://www.ncbi.nlm.nih.gov/pubmed/20004563">A new approach to reduce number of split fields in large field IMRT.</a>&rdquo;</em> Med Dosim. [Epub ahead of print]<br />&nbsp;</p>
<p>16. Chen CC, Lee CC, Mah D, Sharma R, Landau E, <strong>Garg M,</strong> Wu A. <em>&ldquo;<a href="http://www.ncbi.nlm.nih.gov/pubmed/20202815">Dose sparing of brainstem and spinal cord for re-irradiating recurrent head and neck cancer with intensity-modulated radiotherapy.</a></em>&rdquo; Med Dosim. 2010 Mar 3. [Epub ahead of print]<br />&nbsp;</p>
<p>17. Quon H, Yom SS, <strong>Garg MK,</strong> Lawson J, McDonald MW, Ridge JA, Saba N, Salama J, Smith R, Yeung AR, Beitler JJ <em>&ldquo;<a href="http://www.ncbi.nlm.nih.gov/pubmed/20541056">ACR Appropriateness Criteria: local-regional therapy for resectable oropharyngeal squamous cell carcinomas.</a></em>&rdquo;Curr Probl Cancer. 2010 May-Jun;34(3):175-92. Review<br />&nbsp;</p>
<p>18. C. R. Salazar, R. V. Smith, <strong>M. Garg,</strong> M. Haigentz Jr., B. Schiff, N. Kawachi, J. Ostoloza, T. J. Belbin, M. B. Prystowsky, R. D. Burk, N. F. Schlecht : <em>&ldquo;Human papillomavirus associated survival and response to therapy in head and neck squamous cell carcinoma&rdquo;</em> Manuscript submitted to Annals of Oncology.<br />&nbsp;</p>
<p>19. Expert Panel on Radiation Oncology-Head and Neck, Salama JK, Saba N, Quon H, <strong>MK</strong> <strong>Garg,</strong> Lawson J, McDonald MW, Ridge JA, Smith RV, Yeung AR, Yom SS, Beitler JJ. <em>ACR appropriateness criteria&reg; adjuvant therapy for resected squamous cell carcinoma of the head and neck.</em> Oral Oncol. 2011 Jul;47(7):554-9. Epub 2011 Jun 12.</p>
<p>20. McDonald MW, Lawson J, <strong>Garg MK,</strong> Quon H, Ridge JA, Saba N, Salama JK, Smith RV, Yeung AR, Yom SS, Beitler JJ; Expert Panel on Radiation Oncology-Head and Neck Cancer. <em>ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer.</em> Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1292-8. Epub 2011 Apr 27. Review.&nbsp;<br />&nbsp;</p>
<p>21. Hong LX, <strong>Garg M,</strong> Lasala P, Kim M, Mah D, Chen CC, Yaparpalvi R, Mynampati D, Kuo HC, Guha C, Kalnicki S. <em>Experience of micromultileaf collimator linear accelerator based single fraction stereotactic radiosurgery: tumor dose inhomogeneity, conformity, and dose fall off. </em>Med Phys. 2011 Mar;38(3):1239-47</p>
<p>22. Ahn PH, Chen CC, Ahn AI, Hong L, Scripes PG, Shen J, Lee CC, Miller E,Kalnicki S, <strong>Garg MK.</strong> <em>Adaptive planning in intensity-modulated radiation therapy for head and neck cancers: single-institution experience and clinical implications</em>. Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):677-85. Epub 2010 Jul 9.</p>
<p>23. Saini G, Aggarwal A, Chomal M, Srivastava R, Sharma PK, Nangia S, Garg M<em>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21981875">Cranio-spinal irradiation with volumetric modulated arc therapy: a multi-institutional treatment experience.</a> </em>Radiother Oncol. 2012 Feb;102(2):322; Epub 2011 Oct 6.</p>
<p>24. Yeung AR, Garg MK, Lawson J, McDonald MW, Quon H, Ridge JA, Saba N, Salama JK, Smith RV, Yom SS, Beitler JJ; <em><a href="http://www.ncbi.nlm.nih.gov/pubmed/22250010">ACR Appropriateness Criteria&reg; ipsilateral radiation for squamous cell carcinoma of the tonsil.</a> </em>Expert Panel on Radiation Oncology--Head &amp; Neck Cancer American College of Radiology. Head Neck. 2012 May;34(5):613-6. doi: 10.1002/hed.21993. Epub 2012 Jan 17.</p>
<p>25. Garg MK, Glanzman J, Kalnicki S. <em><a href="http://www.ncbi.nlm.nih.gov/pubmed/22840597">The evolving role of positron emission tomography-computed tomography in organ-preserving treatment of head and neck cancer.</a> </em>Semin Nucl Med. 2012 Sep;42(5):320-7. doi: 10.1053/j.semnuclmed.2012.04.005. Review.</p>
<p>26. Garg MK, Ridge JA, Yom SS, McDonald MW, Quon H, Smith RV, Yeung AR, Lawson J, Saba N, Salama JK, Beitler JJ. <em>Reply, contralateral irradiation for T(limited)N2bM0 lateralized tonsil cancer.</em> Head Neck. 2013 Mar;35(3):465-6. doi: 10.1002/hed.23212. Epub 2013 Feb 5. No abstract available.<br />&nbsp;</p>
<p>27. Ohri N, Garg MK, Aparo S, Kaubisch A, Tome W, Kennedy TJ, Kalnicki S, Guha C.<em>Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis.&nbsp; </em>Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):330-5. doi: 10.1016/j.ijrobp.2013.02.008. Epub 2013 Mar 20. Review.<br />&nbsp;</p>
<p>28. Gez E, Cytron S, Ben Yosef R, London D, Corn BW, Alani S, Scarzello G, Dal Moro F, Sotti G, Zattoni F, Koziol I, Torre T, Bassignani M, Kalnicki S, Ghavamian R, Blakaj D, Anscher M, Sommerauer M, Jocham D, Melchert C, Huttenlocher S, Kovacs G, Garg M. <em>Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study.</em> Radiat Oncol. 2013 Apr 23;8:96. doi: 10.1186/1748-717X-8-96.<br />&nbsp;</p>
<p>29. Mourad WF, Young BM, Young R, Blakaj DM, Orhi N, Shourbaji RA, Manolidis S, G&aacute;mez M, Kumar M, Khorsandi A, Khan MA, Shasha D, Blakaj A, Glanzman J, Garg MK, Hu KS, Kalnicki S, Harrison LB. <em>Clinical validation and applications for CT-based atlas for contouring the lower cranial nerves for head and neck cancer radiation therapy. </em>Oral Oncol. 2013 Sep;49(9):956-63. doi: 10.1016/j.oraloncology.2013.03.449. Epub 2013 Apr 25.<br />&nbsp;</p>
<p>30. Ridge JA, Lawson J, Yom SS, Garg MK, McDonald MW, Quon H, Saba N, Salama JK, Smith RV, Worden F, Yeung AR, Beitler JJ. <em>American College of Radiology Appropriateness Criteria(&reg;) treatment of stage I T1 glottic cancer.</em> Head Neck. 2014 Jan;36(1):3-8. doi: 10.1002/hed.23381. Epub 2013 Sep 18. Review.</p>
<p>31. Einarson TR, Zilbershtein R, Skoup&aacute; J, Vesel&aacute; S, Garg M, Hemels ME. <em>Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic. </em>J Med Econ. 2013 Sep;16(9):1089-95. doi: 10.3111/13696998.2013.820193. Epub 2013 Jul 9.&nbsp;<br />&nbsp;</p>
<p>32. Mourad WF, Blakaj DM, Kabarriti R, Young R, Shourbaji RA, Glanzman J, Patel S, Yaparpalvi R, Kalnicki S, Garg MK. <em>Lack of adjuvant radiotherapy may increase risk of retropharyngeal node recurrence in patients with squamous cell carcinoma of the head and neck after transoral robotic surgery.</em> Case Rep Oncol Med. 2013;2013:727904. doi: 10.1155/2013/727904. Epub 2013 Jun 13.<br />&nbsp;</p>
<p>33. Salazar CR, Smith RV, Garg MK, Haigentz M Jr, Schiff BA, Kawachi N, Anayannis N, Belbin TJ, Prystowsky MB, Burk RD, Schlecht NF. <em>Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment.</em> Head Neck Pathol. 2014 Mar;8(1):77-87. doi: 10.1007/s12105-013-0486-4. Epub 2013 Sep 4.<br />&nbsp;</p>
<p>34. Mourad WF, Young R, Kabarriti R, Blakaj DM, Shourbaji RA, Glanzman J, Patel S, Ohri N, Yaparpalvi R, Beitler JJ, Kalnicki S, Garg MK. <em>25-year follow-up of HIV-positive patients with benign lymphoepithelial cysts of the parotid glands: a retrospective review. </em>Anticancer Res. 2013 Nov;33(11):4927-32.<br />&nbsp;</p>
<p>35. Salazar CR, Anayannis N, Smith RV, Wang Y, Haigentz M Jr, Garg M, Schiff BA, Kawachi N, Elman J, Belbin TJ, Prystowsky MB, Burk RD, Schlecht NF. <em>Combined P16 and human papillomavirus testing predicts head and neck cancer survival. </em>Int J Cancer. 2014 Nov 15;135(10):2404-12. doi: 10.1002/ijc.28876. Epub 2014 Apr 17.<br />&nbsp;</p>
<p>36. Salama JK, Golden DW, Yom SS, Garg MK, Lawson J, McDonald MW, Quon H, Ridge JA, Saba N, Smith RV, Worden F, Yeung AR, Beitler JJ. <em>ACR Appropriateness Criteria&reg; thyroid carcinoma.</em> Oral Oncol. 2014 Jun;50(6):577-86. doi: 10.1016/j.oraloncology.2013.12.004.<br />&nbsp;</p>
<p>37. Kawashita Y, Deb NJ, Garg MK, Kabarriti R, Fan Z, Alfieri AA, Roy-Chowdhury J, Guha C. <em>An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.</em> Radiat Res. 2014 Aug;182(2):201-10. doi: 10.1667/RR13617.1. Epub 2014 Jul 3.<br />&nbsp;</p>
<p>38. Kawashita Y, Deb NJ, Garg M, Kabarriti R, Alfieri A, Takahashi M, Roy-Chowdhury J, Guha C. <em>An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 1. Flt3 ligand gene transfer increases antitumor effects of a radio-inducible suicide gene therapy in an ectopic tumor model.</em> Radiat Res. 2014 Aug;182(2):191-200. doi: 10.1667/RR13594.1. Epub 2014 Jun 27.<br />&nbsp;</p>
<p>39. Yaparpalvi R, Mehta KJ, Bernstein MB, Kabarriti R, Hong LX, Garg MK, Guha C, Kalnicki S, Tom&eacute; WA. <em>Contouring and constraining bowel on a full-bladder computed tomography scan may not reflect treatment bowel position and dose certainty in gynecologic external beam radiation therapy.</em> Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):802-8. doi: 10.1016/j.ijrobp.2014.07.016. Epub 2014 Sep 20.<br />&nbsp;</p>
<p>40. Kabarriti R, Ohri N, Hannan R, Tishbi N, Baliga S, McGovern KP, Mourad WF, Ghavamian R, Kalnicki S, Guha C, Garg MK. <em>Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure. </em>Pract Radiat Oncol. 2014;4(6):409-14. doi: 10.1016/j.prro.2014.01.002. Epub 2014 Feb 22.<br />&nbsp;</p>
<p>41. Hong LX, Shankar V, Shen J, Kuo HC, Mynampati D, Yaparpalvi R, Goddard L, Basavatia A, Fox J, Garg M, Kalnicki S, Tom&eacute; WA. <em>Spine stereotactic body radiation therapy plans: Achieving dose coverage, conformity, and dose falloff.</em> Med Dosim. 2014 Dec 10. pii: S0958-3947(14)00125-3. doi: 10.1016/j.meddos.2014.11.002. [Epub ahead of print]</p>
<p>42. Ohri N, Rapkin BD, Guha D, Haynes-Lewis H, Guha C, Kalnicki S, Garg M. <em>Predictors of radiation therapy noncompliance in an urban academic cancer center. </em>Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):232-8. doi: 10.1016/j.ijrobp.2014.09.030.<br />&nbsp;Ow TJ, Pitts CE, Kabarriti R, Garg MK. <em>Effective Biomarkers and Radiation Treatment in Head and Neck Cancer. </em>Arch Pathol Lab Med. 2015 Jun 5. [Epub ahead of print]</p>
<p>43. Kabarriti R, Mark, D, Garg, MK.<em> Proton therapy for the treatment of pediatric head and neck cancers: a review. </em>J Ped Otorhinolaryng 2105 [in Press]</p>
<p><br />&nbsp;44. Paul B. Romesser, Oren Cahlon,Eli D. Scher, Eugen B. Hug,Kevin Sine, Carl DeSelm, Jana L. Fox, Dennis Mah, Madhur K. Garg, John Han-Chih Chang, and Nancy Y. Lee:<em> &ldquo;Proton Beam Re-Irradiation for Recurrent Head and Neck Cancer: Multi-Institutional Report on Feasibility and Early Outcomes&rdquo;:</em>Int J Radiat Oncol Biol Phys. 2015 (in press)</p>

EMR ID

4254

Biography

<p>Madhur Garg earned his medical degree at King George&rsquo;s Medical College and completed his residency in radiation oncology at Rush-Presbyterian-St. Luke&rsquo;s Hospital in Chicago and Montefiore in New York City. He also completed a specialized fellowship at Wayne State University in Detroit.</p><p>Dr. Garg is the recipient of the prestigious American Society of Clinical Oncology&rsquo;s Young Investigator's Award and the Department of Defense Physician Research Award. He is listed as one of the &ldquo;New York Top Doctors,&rdquo; &ldquo;America&rsquo;s Top Oncologists&rdquo; and &ldquo;Best Doctors in America.&rdquo;</p><p>Dr. Garg serves on several Montefiore and Einstein committees, as well as international societies such as the American Society of Clinical Oncology, the American College of Radiology and the American Society for Radiation Oncology. He is on the review boards for several journals, including <em>International Journal of Radiation Oncology &bull; Biology &bull; Physics</em>.</p>

Is Open Scheduling

Off

Jana L. Fox

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/f6b22b70-d525-11eb-af57-a79c115e5bbd.jpg

First Name

Jana

Last Name

Fox

NPI

1154467363

Faculty ID

13179

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5426

Is Open Scheduling

Off

Celina Crisman

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/5f9771e0-4245-11ec-9f43-cb1a79f37024.jpg

First Name

Celina

Last Name

Crisman

NPI

1255699963

Faculty ID

17951

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Neurosurgical oncology and focuses on the diagnosis and surgical treatment of cranial lesions in adult patients

Elsevier Profile

EMR ID

163350

Biography

<p>Celina Crisman , MD, MPH, is an attending physician and Assistant Professor, Neurological Surgery at Montefiore Einstein. Dr. Crisman specializes in neurosurgical oncology and focuses on the diagnosis and surgical treatment of cranial lesions in adult patients. Through a dedicated fellowship, she received specialized training in surgical approaches to benign and malignant cranial tumors and enjoys applying the most advanced techniques and surgical adjuncts to each case. Dr. Crisman performs awake tumor resection when indicated and works closely with a multidisciplinary team to maximize resection of tumors in eloquent regions. She also cares for patients with general neurosurgical needs ranging from hydrocephalus, chiari malformation and herniated discs, as well as traumatic bleeds.</p><p>Dr. Crisman obtained her Bachelor of Science in biology and biology and society from Cornell University, and earned her Doctor of Medicine from Columbia University Valegos College of Physicians and Surgeons. She completed her residency in neurological surgery at Rutgers University and was a neurosurgical oncology fellow at Memorial Sloan Kettering. Dr. Crisman also earned a Masters in Public Health from the Harvard Chan School of Public Health.</p>

Is Open Scheduling

On